catalyst · primary record
Neridronate + Placebo
Phase readout · 2027-12-01 · Complex Regional Pain Syndrome Type I
| Company | Ambros Therapeutics, Inc. |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT07210515 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:50.845Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Ambros Therapeutics, Inc.:Neridronate + Placebo:2027-12-01:P3 primary completion · NCT07210515
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.